Key Points
- COO Liane Rae Teplitsky bought shares in two transactions, acquiring a combined 2,070 Pulse Biosciences shares for approximately $99,960 at prices near $48 per share.
- Pulse Biosciences shares opened at $47.57 after falling 2%; the company reported a quarterly loss of $0.36 per share and revenue of $0.43 million, both worse than analyst expectations.
- Analyst sentiment remains generally positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus and a $45.25 average price target; institutional investors own 76.95% of the stock.
Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) COO Liane Rae Teplitsky acquired 1,036 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The shares were acquired at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the transaction, the chief operating officer owned 1,036 shares of the company's stock, valued at approximately $49,966.28. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Liane Rae Teplitsky also recently made the following trade(s):
- On Friday, August 28th, Liane Rae Teplitsky bought 1,034 shares of Pulse Biosciences stock. The stock was acquired at an average cost of $48.35 per share, with a total value of $49,993.90.
Pulse Biosciences Stock Down 2.0%
Shares of PLSE opened at $47.57 on Friday. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of -40.31 and a beta of 1.61. The company's fifty day moving average is $35.38 and its 200-day moving average is $27.00. Pulse Biosciences, Inc has a 12 month low of $12.56 and a 12 month high of $50.90.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The business had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. As a group, research analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research firms recently weighed in on PLSE. Weiss Ratings restated a "sell (d-)" rating on shares of Pulse Biosciences in a report on Friday, July 17th. Oppenheimer reiterated an "outperform" rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Needham & Company LLC began coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They issued a "buy" rating and a $58.00 price target on the stock. Canaccord Genuity Group boosted their price objective on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Finally, Mizuho set a $45.00 price objective on shares of Pulse Biosciences in a report on Monday, August 10th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $45.25.
View Our Latest Stock Analysis on PLSE
Institutional Investors Weigh In On Pulse Biosciences
Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. increased its position in Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock worth $70,000 after acquiring an additional 619 shares during the period. BNP Paribas Financial Markets raised its stake in Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock valued at $26,000 after purchasing an additional 680 shares during the last quarter. Osterweis Capital Management Inc. bought a new stake in Pulse Biosciences in the 2nd quarter valued at $28,000. Alliancebernstein L.P. boosted its holdings in Pulse Biosciences by 6.7% in the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company's stock valued at $365,000 after purchasing an additional 1,300 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after purchasing an additional 2,156 shares during the period. Institutional investors and hedge funds own 76.95% of the company's stock.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
